Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could 2 days of antibiotics be enough for deadly Flesh-Eating infections?

NCT ID NCT06002607

Disease control Sponsor: University of California, Irvine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a 48-hour course of antibiotics to a standard 7-day course for people with severe, life-threatening skin infections called necrotizing soft tissue infections. Researchers want to see if the shorter treatment is just as safe and effective. The trial will enroll 50 adults in the emergency department and track complications and survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Antibiotics (Clindamycin, Vancomycin, Piperacillin Tazobactam)
What this could lead to
If successful, this could show that a shorter antibiotic course is safe for patients with severe skin infections, potentially reducing side effects and hospital stays.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to everyone. The shorter course might not control the infection as well, leading to higher complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patients with a diagnosis of Necortizing Soft Tissue Infection who undergo consultation by the Emergency General Surgery service.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patients 18 years of age or older with all following criteria: * Presenting to the Emergency Department with history, exam and/or imaging concerning NSTI, AND * Patients who undergo consultation by the Emergency General Surgery service, AND * Patients included must have skin or soft tissue findings consistent with NSTI (erythema, crepitus, or pain out of proportion to exam), AND * Systemic signs of infection including fever (temperature \>38.0°C) or leukocytosis (≥11,000 peripheral white cells per cubic millimeter), AND * Patients who undergo excisional debridement and/or amputation to achieve source control. Exclusion Criteria: * Pregnant patients * Prisoners * Patients with bacteremia upon admission * Patients unable to provide consent (including no legally authorized representative)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Necrotizing soft tissue infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

necrotizing soft tissue infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Necrotizing soft tissue infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of California Irvine Medical Center

    RECRUITING

    Orange, California, 92868, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.